Berlin Cures Boosts Research and Development with New Advisory Board

Berlin Cures Holding AG, a promising player in the biotechnology sector focusing on the treatment of Long COVID, announced the formation of a new advisory board on April 3, 2024. This strategic move aims to enhance the company's research capabilities and tap into the immense scientific knowledge of six distinguished scientists. The newly formed board is expected to guide Berlin Cures on industry developments, explore new growth opportunities, and bolster the research and development efforts for new therapies.

The advisory board consists of experts across various medical fields, including neuroimmunology, cardiomyopathy, ophthalmology, medical cardiology, and immunology, all of whom have significant achievements in their respective areas. This interdisciplinary team is set to play a crucial role in advancing Berlin Cures' mission to develop innovative therapies for diseases associated with functional autoantibodies. Diseases such as Long COVID, heart failure, glaucoma, and ME/CFS are the company's primary focus.

Berlin Cures is currently conducting a Phase II clinical trial for its pioneering drug BC 007 aimed at treating Long COVID. The trial, which started in June 2023, is progressing successfully across five countries and 12 study centers. With over 75% of the target participants already enrolled, the study results, expected in autumn 2024, are highly anticipated to lead into a Phase III study. This step is crucial for receiving regulatory approval and furthering the clinical development of Berlin Cures' other programs. Oliver von Stein, CEO of Berlin Cures, expressed enthusiasm about working with the advisory board and emphasized the company's commitment to innovative research and providing effective therapies for autoantibody-associated diseases.